Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL.
about
Oxidized Low-Density Lipoprotein Immune Complex Priming of the Nlrp3 Inflammasome Involves TLR and FcγR Cooperation and Is Dependent on CARD9Clinical significance of the humoral immune response to modified LDL.Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress.Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.Adaptive immunity and adipose tissue biologyB lymphocytes in human subcutaneous adipose crown-like structuresLDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses.Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.Lipoprotein autoantibodies: measurement and significance.Reduced Atherosclerosis in apoE-inhibitory FcγRIIb-Deficient Mice Is Associated With Increased Anti-Inflammatory Responses by T Cells and MacrophagesAccelerated vascular disease in systemic lupus erythematosus: role of macrophage.Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC CohortHigh concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes.Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease.Putative consequences of exposure to Helicobacter pylori infection in patients with coronary heart disease in terms of humoral immune response and inflammationAltered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritisDistribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.Atherogenesis and the humoral immune response to modified lipoproteinsAtherosclerosis and systemic lupus erythematosus: mechanistic basis of the association.Autoimmune-mediated atherothrombosis.Elevated Levels of Plasma IgA Autoantibodies against Oxidized LDL Found in Proliferative Diabetic Retinopathy but Not in Nonproliferative RetinopathyOxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytesThe role of immune complexes in atherogenesis.Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases.Highly electronegative low-density lipoprotein L5 evokes microglial activation and creates a neuroinflammatory stress via Toll-like receptor 4 signaling.The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes.The activation of CD14, TLR4, and TLR2 by mmLDL induces IL-1β, IL-6, and IL-10 secretion in human monocytes and macrophages.Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells.Plasma IgA antibody levels to malondialdehyde acetaldehyde-adducts are associated with inflammatory mediators, obesity and type 2 diabetes.Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes.A role for autoantibodies in atherogenesis.
P2860
Q30274903-33BB7CB4-006D-4FC9-A8F8-5153E1D11E93Q33598770-80FD6102-2FDA-469A-82BE-40A44480731BQ33686991-DE4EB186-7ACB-4B38-8025-B8DA74171571Q34072528-AC8AF009-BF10-4D67-9DD0-9BCD528DF3F1Q34172928-9521F818-3F6D-489E-8994-633A5B8BD66AQ34186722-0FD99163-F868-48CD-9D29-466A2CA0CF78Q34300099-7EFB9A85-9B79-436A-9FB2-C4F69EE0E39BQ34542912-10F21B44-C4E4-4DF5-B903-70DF829058C3Q35140009-B175CEC5-07E3-4A9C-9775-620D7F8262EDQ35537314-FDF1B4F5-D6BB-48FD-89AF-D5EFBD73B49AQ35539166-2D2C3173-AEC7-4BD8-B789-F02D875DCE84Q35769521-89BA6761-BC04-4427-8A81-403B3D033729Q35976427-F802B010-1638-4AC1-88DC-91233F79D241Q36362707-667C421C-33CA-4C2F-87C5-1CCE419F6E94Q36582329-9C565BB3-654C-4A23-87AD-8BFEA8209838Q36955395-6C94092C-F1F2-43A4-8A53-FEC25D43813FQ37012519-E0943E1E-F7A0-4CB3-96C3-6FD782AB9099Q37021490-62BE9A3B-9D9D-4C45-9D7A-C073B9AF308EQ37033339-28C42788-67F8-4571-8ABE-3C19622F532BQ37283009-CFB0D99C-FF5E-43BE-9FE2-8E252A0A154FQ37549608-7DBF4D6C-4F0F-4D4C-A835-7A5718256FDFQ37584378-0732D6A1-073E-43DF-B9A8-B0133B0198A2Q37716355-57200A4D-474F-4D92-8C6B-DF170DE93BBFQ37731718-EA68913E-5B55-4740-8D6B-2F3AA321CFCFQ38078691-CCFA840C-7CB4-4865-ADF4-B94C1C614881Q38819005-08120FC6-559E-45E5-9A7A-0E8F519EBA41Q42201820-4038FA40-44A3-4C52-8834-AA5C538D79C0Q42396872-3081488C-B2D7-4A47-8390-FC7845CCEE0FQ43193872-E8F418F8-A77D-44E0-ADFC-643EA2499B08Q43523503-FE46960F-15B7-45FB-A3BB-72AA730CD13EQ46380048-21BF8F25-5024-41EC-A039-0BBAD43BB127Q47623831-5E347225-477B-4310-BAF3-37E9DDDFC8BB
P2860
Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Proatherogenic and proinflamma ...... DL antibodies and human oxLDL.
@en
Proatherogenic and proinflamma ...... DL antibodies and human oxLDL.
@nl
type
label
Proatherogenic and proinflamma ...... DL antibodies and human oxLDL.
@en
Proatherogenic and proinflamma ...... DL antibodies and human oxLDL.
@nl
prefLabel
Proatherogenic and proinflamma ...... DL antibodies and human oxLDL.
@en
Proatherogenic and proinflamma ...... DL antibodies and human oxLDL.
@nl
P2093
P356
P1433
P1476
Proatherogenic and proinflamma ...... DL antibodies and human oxLDL.
@en
P2093
DCCT/EDIC Research Group
Maria F Lopes-Virella
Sinikka Koskinen
P356
10.1006/CLIM.2002.5269
P577
2002-10-01T00:00:00Z